We are a VC fund focused on investing in early-stage companies in the healthcare sector: biotechnology, medical devices and eHealth.
Invivo Ventures is managed by Invivo Capital Partners, promoted by Luis Pareras and Albert Ferrer, with the experience gained through the first fund Healthequity. The fund was registered to the Comisión Nacional del Mercado de Valores (CNMV) in March 2019 and has achieved a first closing of 40M €.
We are a team of highly qualified professionals, with the scientific, technical and financial know-how required to analyse and make investments to provide value to the invested company. We also have a network of contacts and key strategic relationships in the health ecosystem.
Our company is financed by the European Investment Fund, the Instituto de Crédito Oficial, the Institut Català de Finances, the Institut Valencià de Finances and other private investors.
Projects
We seek projects according to the following criteria:
Investment size
We set initial investments in the range of 0.5-2M €, and after achieving pre-established milestones we can reach up to 4M €.
State of development
We focus on investing in companies in early stages, mainly in the technology transfer phase. In the case of biotechnology companies, they should have a solid proof of concept in animal models, and in the case of medical devices or digital health companies, a prototype close to the market.
Geographical focus
We invest in Spain a significant amount of the funds raised, while a smaller percentage is considered for investments syndicated with other funds in European companies.
Sector
We want to diversify risks by investing in companies in different stages and different sub-sectors within the biomedical area, such as biotechnology, medical devices and digital health.
Healthequity is a VC fund focused on investing in early-stage companies in the Healthcare sector. Promoted by the Medical Association of Barcelona and the financial group Riva y Garcia, it was registered with the CNMV and founded in 2012.
The fund finished its first investment period in early 2019.
Every crisis brings risks and opportunities to the table… here’s a mind map on how SARS-CoV-2 can impact the activities and value chain of the life sciences VC industry
Most rare diseases still lack approved treatments despite major advances in the knowledge of their molecular basis. Here’s a map of the different therapeutic modalities plus an update on some of the most interesting new developments in each field.
The vaccine effort for #COVID19 is unprecedented in scale & speed. To get it right and fast we need new tools and strategies including DNA/RNA vaccines, virus-like particles, T-cell inducing peptides & viral vectors… here’s a map of the leading edge
Fund financed by FEDER: